Thursday, Fennec Pharmaceuticals Inc. (FENC) disclosed that the FDA's Center for Drug Evaluation and Research has issued a public reminder to healthcare providers regarding the company's Pedmark.
The reminder emphasizes that Pedmark or sodium thiosulfate injection should not be substituted with other sodium thiosulfate or STS products, as stated in its prescribing label.
The FDA highlighted that such substitutions pose potential health risks, including exposure to potassium chloride, overexposure to boric acid, and overexposure to sodium nitrite.
The FDA issued this warning as certain providers may be preparing other STS products for patient use instead of Pedmark.
Pedmark is the first and only FDA-approved therapy indicated to reduce the risk of ototoxicity or permanent hearing loss associated with cisplatin in pediatric patients 1 month of age and older.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.